Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

33.01 +1.21 (+3.79%)
Streaming Delayed Price Updated: 12:02 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Incyte Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
On Thursday, Incyte stock hit a key performance benchmark, with its Relative Strength (RS) Rating jumping to 82, up from 78 the day before. 
Via Investor's Business Daily
News headline image
Vertex Pharmaceuticals Stock Sees Rising Relative Strength ↗
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
3 Biotech Companies to Watch in 2023 ↗
These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year. 
Via InvestorPlace
News headline image
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
News headline image
Moderna Stock Shows Surprising Strength; Key Rating Upgraded ↗
See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average. 
Via Investor's Business Daily
News headline image
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
From Genmab A/S
Via Business Wire
News headline image
Our 7 Top Biotech Stock Picks for 2023 ↗
Following the devastation of Covid-19, there’s greater interest toward medical innovations, thus bolstering biotech stock picks for 2023. 
Via InvestorPlace
News headline image
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating ↗
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
News headline image
3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗
These companies have long runways of growth ahead 
Via The Motley Fool
News headline image
Is AbbVie Stock a Buy Now? ↗
The pharmaceutical company prepared well as Humira approaches its patent cliff next year. 
Via The Motley Fool
News headline image
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab
Via Business Wire
News headline image
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84 ↗
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84. 
Via Investor's Business Daily
News headline image
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
News headline image
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
News headline image
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink ↗
You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark ↗
In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday. 
Via Investor's Business Daily
News headline image
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating ↗
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before. 
Via Investor's Business Daily
News headline image
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength ↗
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. 
Via Investor's Business Daily
News headline image
Pacira Pharmaceuticals Stock Shows Rising Relative Strength ↗
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73. 
Via Investor's Business Daily
News headline image
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment ↗
 
Via Benzinga
News headline image
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating ↗
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99. 
Via Investor's Business Daily
News headline image
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade ↗
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. 
Via Investor's Business Daily
News headline image
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98 ↗
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before. 
Via Investor's Business Daily
News headline image
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93. 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.